Journal of Clinical Oncology
Articles in this Issue
Prognostic value of estrogen receptor (ER) and progesterone receptor (PR) expression levels in <i>de novo</i> and recurrent HR+/HER2- metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET): Real-world evidence.
e13078 Background: Differences in clinical outcomes have been observed between pts with de novo (dnMBC) and recurrent metastatic b...
A multi-center case-control study on osteoporosis risk in cancer patients receiving chemotherapy.
12033 Background: Chemotherapy and cancer can worsen osteoporosis, a growing concern with improved cancer survival rates. This study aimed to assess osteo...
Overall survival and biomarker results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC).
4594 Background: The first results of NureCombo revealed the combination of NIVO + ABX followed by RC and adjuvant NIVO was active in pts with MIBC (Merci...
Trends in cancer burden in Pakistan: A 30-year analysis from the global burden of disease study (1990-2019).
e22541 Background: Cancer is a leading cause of mortality worldwide, with significant regional disparities in its burden. In Pakistan, the sixth most popu...
Hospitalization patterns in metastatic melanoma patients with and without sepsis.
e21554 Background: Metastatic melanoma is an aggressive malignancy with a high risk of complications, including sepsis, a significant cause of morbidity a...
Neoadjuvant treatments for resectable (RPC) and borderline resectable pancreatic adenocarcinoma (BRPC): A pairwise and network meta-analysis (NMA).
e16448 Background: Pancreatic adenocarcinoma prognosis is dismal despite the therapeutic advances so far. The only curative chance is represented by surge...
Association of driving distance to clinic with treatment route and dosing for metastatic breast cancer.
e13077 Background: High travel burden is associated with worse cancer outcomes. Travel distance also influences cancer treatment; for example, women who t...
Circulating tumor DNA as an early response indicator in anal squamous cell carcinoma treated with chemoradiation.
3518 Background: Definitive chemoradiation (CRT) is a highly effective, organ-preserving treatment for localized anal squamous cell carcinoma (ASCC). Howe...
Efficacy of adebrelimab with chidamide, gemcitabine, and S-1 in locally advanced or metastatic pancreatic cancer: A phase II study.
e16365 Background: Pancreatic cancer is an aggressive, immunologically “cold” tumor with an immunosuppressive microenvironment. Immune checkpoint inhibito...
Integrin α <sub>V</sub> β <sub>3</sub> -targeted imaging for identification of lung cancer and mapping of lymph-node metastases: A prospective, multicenter, self-controlled phase 3 trial (TRIIL study).
8017 Background: Integrin α V β 3 mediates tumor formation, invasion, metastasis and angiogenesis....
BEP in intermediate- and poor-risk advanced non-seminomatous germ cell tumor (NSGCT): Standing the test of time.
5026 Background: Bleomycin, etoposide, and cisplatin (BEP) has been the cornerstone of treatment for advanced NSGCT for decades. With the advent of newer...
Older-onset hereditary breast and ovarian cancer (HBOC) syndrome patients and clinical value of germline multigene testing.
e12548 Background: Germline genetic testing referral of HBOC syndrome and relevant cancer patients is being undertaken using criteria that maximize the pr...
Demographic and clinical disparities in early mortality of metastatic melanoma patients: A SEER-based analysis (2000–2021).
e21551 Background: Metastatic melanoma is a devastating disease with significant disparities in survival outcomes across demographic and clinical subgroup...
Outcome of localized therapy for residual or recurrent oligo melanoma or renal cell cancer (RCC) following immune checkpoint inhibition therapy (ICI).
e14665 Background: Melanoma and RCC care has been revolutionized by ICI, rendering many patients long term disease progression free. ICI response outcome...
Characterization of salivary CD44 and total protein levels in patients with oral cavity dysplasia.
e18120 Background: Previous studies have identified altered salivary CD44 and total protein (TP) levels in patients with oral cavity cancer (OCC), suggest...
Clinical outcomes of patients with primary refractory metastatic renal cell carcinoma receiving second-line (2L) therapies: An International Metastatic Database Consortium (IMDC) study.
4555 Background: A subset of patients (pts) with metastatic renal cell carcinoma (mRCC) receiving contemporary first line (1L) immune checkpoint inhibitor...
ImmunoSarc2 (Cohort 7a): A Spanish Sarcoma Group (GEIS) phase Ib trial of epirubicin and ifosfamide plus nivolumab in first line of advanced undifferentiated pleomorphic sarcoma (UPS).
11514 Background: It was hypothesized that anthracycline-based chemotherapy plus anti-PD1 (nivolumab) could enhance the activity of upfront chemotherapy i...
Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial: RARE 2 talazoparib and temozolomide.
3155 Background: Preclinical data generated from NIH/NCI Patient-Derived Models Repository (PDMR) demonstrated significant synergistic activity of talazop...
Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer.
1096 Background: Bria-IMT is a combination immunotherapy consisting of allogeneic whole cell cancer vaccine (SV-BR-1-GM) administered w/ immune checkpoint...
Dissecting B-cell responses in high grade serous ovarian cancer.
e14562 Background: T cell-based immunotherapies have demonstrated great success for the treatment of many solid tumors, but not all tumor types and patien...
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: Results from a global multi-site chart review.
9532 Background: Anti-PD-1 immunotherapy has been approved for the treatment of stage III and IV melanoma. Real-world data on its resistance is needed to...
Cost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States.
11049 Background: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are an efficacious treatment for HR-positive (HR+), HER2-negative (HER2-) early brea...
Clinical implications of HER3 overexpression in a diverse patient cohort with prostate cancer.
5081 Background: Prostate cancer (PCa) contributes to almost 15% of US cancer cases annually with significant racial disparities, where black men are more...
Safety of fruquintinib in young and late-elderly Chinese patients with colorectal cancer in real-world clinical practice: Age subgroup analysis of a fruquintinib phase IV study.
e15512 Background: Most patients with colorectal cancer (CRC) are aged ≥65 years, but late elderly patients (≥75 years) are underrepresented in previous s...
A randomized phase 2 trial of flexible and extended dosing of <sup>177</sup> Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT): Trial in progress update.
TPS5121 Background: The U.S. Food and Drug Administration (FDA) approved 177 Lu-PSMA-617 radiopharmaceutical therapy (RPT) for pat...